Pharvaris N.V annual r&d spending
2018
2019
2020
2021
2022
2023
2024
2025
Pharvaris N.V R&D Spending Growth & History (PHVS)
Pharvaris N.V's r&d spending was €124.5M for fiscal 2025.
View full Pharvaris N.V company overviewPharvaris N.V annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €124.5M | €25.9M | +26.29% |
| 2024 | 2024-12-31 | €98.6M | €33.0M | +50.31% |
| 2023 | 2023-12-31 | €65.6M | €8.2M | +14.29% |
| 2022 | 2022-12-31 | €57.4M | €21.6M | +60.32% |
| 2021 | 2021-12-31 | €35.8M | €16.3M | +83.46% |
| 2020 | 2020-12-31 | €19.5M | €13.8M | +243.18% |
| 2019 | 2019-12-31 | €5.7M | €2.0M | +55.94% |
| 2018 | 2018-12-31 | €3.6M | — | — |
Pharvaris N.V quarterly r&d spending
Q2.21
Q2.22
Q2.23
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €35.0M | €5.4M | +18.21% |
| Q1 2026 | 2026-03-31 | €30.2M | −€753,231 | −2.44% |
| Q4 2025 | 2025-12-31 | €34.1M | — | — |
| Q3 2025 | 2025-09-30 | €29.8M | — | — |
| Q2 2025 | 2025-06-30 | €29.6M | €6.5M | +28.35% |
| Q1 2025 | 2025-03-31 | €30.9M | — | — |
| Q2 2024 | 2024-06-30 | €23.1M | €8.4M | +57.12% |
| Q2 2023 | 2023-06-30 | €14.7M | €960,298 | +7.00% |
| Q2 2022 | 2022-06-30 | €13.7M | €5.7M | +70.23% |
| Q2 2021 | 2021-06-30 | €8.1M | — | — |
Pharvaris N.V r&d spending trends
Over the last five fiscal years, Pharvaris N.V's r&d spending increased from €19.5M to €124.5M, a change of €105.0M. The latest reported quarter, Q2 2026, shows €35.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharvaris N.V source filings ↗